Disclosed are methods of identifying tumor-derived exosomes as an early cancer diagnostic, as well as for staging,
|Publication number||WO2016201064 A1|
|Publication date||Dec 15, 2016|
|Filing date||Jun 9, 2016|
|Priority date||Jun 9, 2015|
|Inventors||Alan Schroit, Adi Gazdar, Ober E. Sally Ward|
|Applicant||The Board Of Regents Of The University Of Texas System|
|Export Citation||BiBTeX, EndNote, RefMan|
|External Links: Patentscope, Espacenet|
DESCRIPTION – DIAGNOSTIC TEST FOR EARLY STAGE CANCER
BACKGROUND This application claims benefit of priority to U.S. Provisional Application Serial No.
62/173,252, filed June 9, 2015, U.S. Provisional Application Senal No. 62/196,695, filed July 24, 2015, and U.S. Provisional Application Serial No. 62/209,200, filed August 24, 2015, the entire contents of each application being incorporated by reference. 1. Field
The present disclosure relates generally to the fields of medicine, oncology and cancer diagnostics. More particularly, the disclosure provides methods, compositions and kits for diagnosing various neoplastic diseases, especially at early, asymptomatic or metastatic stages. Even more particularly, it concerns diagnostic methods for the early detection of cancer by quantifying phosphatidylserine (PS)-expressing tumor-derived cancer exosomes in patient samples.